
    
      Primary Endpoint: To improve the 2 year overall survival in patients with primary treatment
      failure

      * Secondary Endpoints:

        -  Feasibility of early transplantation within a multicenter trial

        -  Leukemia-free survival (LFS) at 2 years from transplantation

        -  Leukemia Response rate at day +30, +90 and 6 months

        -  Cumulative incidence of relapse, death from leukemia, and non-relapse mortality (NRM)

        -  Incidence and severity of acute and chronic Graft-versus-Host disease

        -  Feasibility and safety of early discontinuation of immunosuppressive therapy
    
  